Northwell Health’s Feinstein Institutes for Medical Research has announced the recruitment of patients in three clinical studies, which are designed to eliminate the COVID-19 novel coronavirus.
Roche has announced that it will begin a phase III clinical trial of Actemra/RoActemra (tocilizumab) in hospitalised patients with severe COVID-19 pneumonia.
US pharma company Pfizer said that the phase 3 JADE COMPARE trial for abrocitinib in atopic dermatitis (AD) met its co-primary efficacy endpoints.
Novartis announced today the publication of three pivotal Phase III clinical trials for inclisiran, a potential first-in-class small interfering RNA (siRNA) investigational agent for hyperlipidemia in adults.
AstraZeneca said that Imfinzi (durvalumab) has been demonstrated to have delivered a sustained overall survival (OS) benefit in the final analysis of the phase 3 CASPIAN trial in extensive-stage small cell lung cancer.
Merck announced top-line efficacy results from two ongoing pivotal Phase 3 trials (COUGH-1 and COUGH-2) evaluating the efficacy and safety of gefapixant (MK-7264), an investigational, orally administered, selective P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough.
Moderna has announced the dosing of the first participant in a phase1 study of mRNA-1273, the company’s mRNA vaccine candidate against the novel coronavirus (SARS-CoV-2).
Pfizer and EMD Serono are set to scrap the phase 3 JAVELIN Head and Neck 100 study as it was found that avelumab in addition to chemoradiotherapy (CRT) is unlikely to deliver the desired result.
Adaptive Phage Therapeutics (APT) said that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for the clinical development of PhageBank, a personalized bacteriophage therapeutic for the treatment of MDR and complicated bacterial infections.
Artugen Therapeutics Limited, a Company developing novel live biotherapeutics (LBPs) for patients living with infectious, inflammatory and oncologic diseases announced today the first patient dosed with ART24, the Company’s first clinical product candidate for prevention of recurrence of Clostridium difficile infection (CDI).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.